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IDENTIFICATION OF TMIGD1, A NOVEL CELL ADHESION MOLECULE 
INVOLVED IN HUMAN TROPHOBLAST CELL MIGRATION 
CYNTHIA WANG 
ABSTRACT 
Transmembrane and immunoglobulin domain-containing 1 (TMIGD1) is a newly 
identified cell adhesion molecule that mediates cell-cell interactions and is mainly 
expressed in kidney and colon epithelial cells. In renal epithelial cells, TMIGD1 regulates 
cell proliferation and migration. Human tissue panels showed expression of TMIGD1 in 
placenta; however, the potential function of TMIGD1 in placenta is not known. We 
elected to study the expression and function of TMIGD1 during placentation. This is of 
interest because dysregulation of placental invasion is linked to obstetrical complications 
such as preeclampsia and intrauterine growth restriction (IUGR). We hypothesized that 
TMIGD1 is expressed in trophoblast cells and regulates cell migration during placental 
invasion. 
Placental tissues were subjected to immunofluorescence (IF) staining using anti-
TMIGD1 antibody and TMIGD1 localization in trophoblast was visualized using a 
fluorescence microscope. Additionally, we overexpressed TMIGD1 in the immortalized 
trophoblast cell line, HTR8/SVneo, via a retroviral system. Transduction was verified 
using IF, Western blot, and qPCR to compare the modified and original cell lines. 
Migration of TMIGD1-overexpressing HTR8/SVneo cells was assessed using wound-
healing and transwell migration assays.  
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We observed TMIGD1 localization in the apical region of syncytiotrophoblasts. 
TMIGD1 mRNA expression in the transduced HTR8/SVneo cells was 3-fold greater than 
that in the control line, and 400-fold greater in first trimester whole placenta. TMIGD1-
overexpressing HTR8/SVneo cells exhibited a 30±5% decrease in migration in the 
wound-healing assay, compared to the untransduced cells. Similarly, TMIGD1 
overexpression in HTR8/SVneo suppressed migration by 36%, compared to control cells 
in transwell assays. Fluorescent staining showed that increased TMIGD1 expression 
modifies actin cytoskeleton by redistributing filaments to the peripheries. Additionally, 
cells overexpressing TMIGD1 exhibit a distinct morphology that lacks filopodia or other 
motility structures. 
Our study demonstrates for the first time that TMIGD1 is expressed in trophoblast 
cells and acts to inhibit cell migration. The evidence presented in this study supports the 
idea that TMIGD1 expression in trophoblast may play an important function in regulating 
placental invasion, and that perturbations in its activity may be associated with obstetrical 
complications such as preeclampsia and intrauterine growth restriction.  
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INTRODUCTION 
 
Through numerous physiological functions, the placenta plays an essential role in 
supporting the developing fetus during pregnancy. Key changes in placenta structure and 
activity occur during the first trimester, including placental invasion into the maternal 
decidua and trophoblast differentiation.  
 
Figure 1. Interface between placental villi and maternal uterus. This illustration 
shows the arrangement of trophoblast layers and cell types. Note that two categories of 
extravillous trophoblasts are distinguishable: interstitial, which invade the decidua up to 
the myometrium, and endovascular, which displace smooth muscle cells. Adapted from 
Kweider et al. (2012). 
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At the cellular level, the developing placenta is formed of villous cytotrophoblasts 
(CTBs), which may further differentiate into an epithelial layer of syncytiotrophoblast 
(STBs), as shown in Figure 1. Inter-trophoblastic communication, possibly achieved via 
gap junctions or paracrine signaling, allows the two layers to coordinate invasive activity 
(Bischoff et al., 2000; Cronier et al., 2002). As placenta invasion progresses, CTBs also 
differentiate into extravillous cytotrophoblasts (EVTs), which migrate through the STB 
layer into uterine tissue and form attachments to stabilize the growing fetus in a process 
known as interstitial invasion. Additionally, the EVTs undergo endovascular invasion, 
during which they remodel the maternal spiral arteries by displacing smooth muscle cells 
lining the vessel walls (Cartwright et al., 2002). This results in widening of the arteries, 
lowering resistance and and thus allowing greater blood flow to nourish the fetus. These 
vascular changes ensure sufficient oxygenation throughout pregnancy. 
 
Disorders of deficient placenta invasion: preeclampsia 
Dysregulation of placentation as discussed above may lead to pregnancy 
complications and/or miscarriage. For example, diminished trophoblast invasion is 
observed in cases of preeclampsia and intrauterine growth restriction (IUGR). Figure 2 
shows that trophoblast invasion is more superficial in these disorders, compared to that of 
a normal pregnancy. Furthermore, transformation of the maternal spiral arteries is 
insufficient. Since the placenta fails to initiate the proper changes in vascular resistance, 
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oxygen delivery to the fetus is compromised. Consequently, fetal growth may be be 
diminished or early pregnancy loss may occur. 
 
Figure 2. Remodeling of maternal arteries by invading trophoblasts. During normal 
pregnancy, invading trophoblasts reach the myometrium and begin remodeling 
vasculature. In contrast, cases of preeclampsia and IUGR are characterized by poor 
trophoblast invasion and a failure to widen spiral arteries into low-resistance, high-flow 
uteroplacental vessels. Adapted from Moffet-King (2002). 
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With preeclampsia cases, the mother may suffer from hypertension, edema, and 
proteinuria. If left untreated, she may progress to eclampsia, a life-threatening condition 
characterized by the onset of seizures. This necessitates immediate fetal delivery before 
the condition progresses to multi-organ failure, including renal, hepatic, and 
cardiovascular complications. A variant of preeclampsia includes “HELLP syndrome”, 
an acronym for hemolysis, elevated liver enzymes and low platelets that occurs in 10% to 
20% of preeclampsia cases (Haram et al., 2012). In North America and Western Europe, 
preeclampsia occurs in 2-5% of all pregnancies (Ronsmans et al., 2006), but can range as 
high as 18% in Africa (Villar et al., 2003).  
Preeclampsia is a leading cause of global maternal death, and incidence rates have 
been increasing for the last three decades (Breathett et al., 2014). Advances in maternal 
and neonatal care have improved clinical outcomes that are even more favorable if 
symptoms are recognized and managed early on. However, the mechanisms and factors 
involved in the development of this condition are unclear. Many interdisciplinary 
explanations have been proposed, and it is unlikely that this disorder is limited to a single 
cause. For example, studies have linked preeclampsia to a maladaptive immune response 
(Matthiesen et al., 2005) and inflammation (Redman et al., 1999). One group of 
researchers performed several meta-analyses of genotype studies from MEDLINE and 
Embase databases and found significant associations between preeclampsia and several 
gene groups, including coagulation factors, leptin receptor, and thrombophilic gene 
groups (Fong et al., 2014). However, more systemic reviews and rigorous study designs 
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are necessary to draw conclusions about relative risk for carriers. In general, 
physiological explanations are frequently connected to utero-placental interactions, so the 
placenta remains an important area of focus. Thus, research into the etiology and risk 
factors of preeclampsia are crucial for diagnosis and clinical management. 
 
 
Disorders of excessive placenta invasion: placenta accreta 
While deficient trophoblast invasion is characteristic of multiple pregnancy 
disorders, excessive invasion may lead to life-threatening complications as well. Placenta 
accreta is a serious condition that occurs when the placenta and emerging blood vessels 
invade too deeply into the uterine wall. More severe degrees of placenta accreta include 
placenta increta, when the placenta invades into the myometrial layer, and placenta 
percreta, when the placenta invades beyond the uterine serosa and sometimes into 
neighboring organs such as the urinary bladder (Figure 3). 
The incidence of placenta accreta (and its various forms) has grown in recent 
years to about 1 in 533 pregnancies, based on a retrospective study of cases from 1982-
2002 (Wu et al., 2005). In comparison, the estimated rate in the 1970s was 1 in 4,027 
pregnancies (Read et al., 1980). A likely explanation is the increasing incidence of 
cesarean deliveries (Menacker & Hamilton, 2010); studies have shown that the risk of 
placenta accreta is directly proportional to the number of prior cesarean deliveries, as 
well as the presence of placenta previa, a condition where the placenta develops low in 
the uterus and covers the cervix (Belfort 2010). 
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Figure 3. Different levels of excessive placenta invasion. Compared to a normal 
pregnancy, the placenta attaches to the myometrium in placenta accreta (1), invades 
partially into the myometrium in placenta increta (2), and invades through the uterine 
serosa in placenta percreta (3). Adapted from Reitman et al. (2011). 
 
  
At the time of delivery, the abnormal placenta fails to detach completely from the 
uterus, resulting in severe hemorrhage. Mothers often require multiple blood transfusions, 
surgical removal of placenta tissue, and occasionally, gravid hysterectomies. Suspected 
cases of placenta accreta must be managed with careful preparations to minimize 
complications during delivery. Although the abnormal placental invasion is frequently 
associated with previous damage to the uterine lining such as cesarean section or other 
surgical scarring (Jurkovic et al., 2003), a portion of cases occurs despite no known prior 
endometrial injury (Clark et al., 1985). Thus, studying invasive properties of trophoblasts 
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at the molecular level may provide insight into the mechanisms controlling invasion. 
Identifying regulatory factors will help our understanding of how this condition develops, 
and will provide potential targets for therapies or diagnostic testing. 
 
 
TMIGD1 discovery 
Transmembrane and immunoglobulin domain-containing 1 (TMIGD1) was 
recently characterized in renal tubular epithelial cells as a novel cell adhesion molecule 
(Arafa et al., 2015). Figure 4 shows the two predicted Ig domains of the TMIGD1 
extracellular region, which were found to self-dimerize. This discovery was preceded by 
the identification of its first protein family member, immunoglobulin and proline-rich 
receptor-1 (IGPR-1) encoded by transmembrane and Ig domain-containing 2 (TMIGD2) 
gene in human endothelial and epithelial cells. Rahimi et al. (2012) showed that IGPR-1 
participates in angiogenesis by regulating capillary tube formation and cell migration. 
This prompted further investigation into whether TMIGD1 demonstrates similar adhesive 
properties. Arafa et al. studied protein function by both knocking down and 
overexpressing TMIGD1 in the human embryonic kidney (HEK-293) and human kidney 
tubular (HK2) cell lines, and found evidence that TMIGD1 inhibits kidney cell migration 
and modifies cell morphology by restructuring the actin cytoskeleton. Similarly, IGPR1 
was previously observed to reduce cell migration and regulate actin stress fiber 
remodeling in porcine aortic endothelial (PAE) cells (Rahimi et al., 2012). Additionally, 
TMIGD1 protects cells against oxidative and metabolic stresses, which is essential 
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against the frequent injuries experienced by the renal tubular epithelium. Further research 
is necessary to obtain a clearer picture of mechanisms activating TMIGD1. 
 
Figure 4. Predicted structure of Ig domains of TMIGD1. Using a 3D modeling 
program, this hypothetical protein structure was created based on genomic information. 
Adapted from Arafa et al. (2015) 
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Objectives 
A tissue panel completed prior to our study (unpublished data) demonstrated high 
TMIGD1 expression in whole human placenta. Given the presence of TMIGD1 in the 
placenta and previous evidence that placental invasion shares certain characteristics with 
the process of tumor metastasis, we sought to examine the potential role of TMIGD1 
during placentation. TMIGD1 has been shown to regulate cell proliferation and migration 
in renal epithelial cells. Specifically, it appears to exhibit inhibitory activity, as observed 
in overexpression and knockdown experiments in human kidney cell lines. Furthermore, 
TMIGD1 expression is downregulated in human colon tumors (Cattaneo et al., 2011), 
suggesting that its reduced expression may be permissive of invasion. We therefore 
sought to investigate specific TMIGD1 expression in placenta villi layers and observe 
how overexpression affects trophoblast motility. 
 
The specific aims of our study are:  
1) To visually localize TMIGD1 expression in human placenta at different stages 
of development 
2) To overexpress TMIGD1 in HTR8/SVneo cells using a retroviral vector 
3) To assess cell motility in our transduced HTR8/SVneo cells and observe the 
effects of TMIGD1 overexpression 
4) To analyze actin structure in transduced cells to assess mechanisms 
underlying changes in migratory/invasive behavior 
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We hypothesize that TMIGD1 is expressed in trophoblast cells and regulates cell 
migration during placental invasion. The results of our study would hopefully elucidate 
the role of TMIGD1 in placental development and provide a target for future studies 
related to pregnancy disorders.
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METHODS 
 
IRB-approved discarded human tissue collection 
De-identified discarded first and second trimester human placental tissue was collected 
from pregnancy terminations at the family planning unit of Boston Medical Center under 
IRB approved protocol H-26575.  
 
Immunohistochemistry (IHC) 
Human placental tissue: Placental tissue was fixed and dehydrated in a series of ethanol 
and Pro-Par (xylene substitute) washes before embedding in paraffin wax and mounting 6 
μm sections onto Fisherbrand Superfrost Plus slides. Before staining, sections were 
subjected to a deparaffinization and rehydration treatment consisting of Pro-par, ethanol, 
and distilled water washes. The tissue sections were then placed in Diva Decloaker 1X 
(Biocare Medical cat#DV2004MX) for an antigen-retrieval procedure, performed in a 
pressure cooker to improve epitope recognition by primary antibodies. Tissue sections 
were washed 5 times in PBST (1X PBS+ 0.4% Triton X-100) for 5 minutes each, blocked 
for 20 minutes in 4% donkey serum (Jackson ImmunoResearch Laboratories) in PBST, 
and incubated overnight at 4°C in mouse-anti-HPL (ABCAM cat# AB11396) or rabbit 
anti-TMIGD1, diluted 1:1000 and 1:150 in PBST with 10% horse serum (Vector 
Laboratories), respectively. Sections were washed 3 times in PBST for 5 minutes each, 
blocked for 20 minutes, and incubated for 30 minutes in the dark at room temperature in 
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secondary antibodies CY3-anti rabbit and AlexaFluor 488-anti mouse (Invitrogen), 
diluted 1:1500 in PBST. Sections were washed 3 times in PBST for 5 minutes each and 
coverslipped using VECTASHIELD Mounting Media with DAPI (Vector Laboratories). 
Images were taken using an Olympus BH2-RFCA microscope and attached Olympus 
DP73 camera. 
 
Cell lines: HTR8/SVneo cells (Graham et al., 1993) were seeded onto 22mm coverslips 
in a 6-well plate and incubated at 37°C for 48 hours. Cells were fixed for 15 minutes in 
4% paraformaldehyde, washed 3 times in PBS, permeabilized for 10 minutes in PBST, 
washed 3 times in PBS, blocked for 30 minutes, and incubated for 90 minutes in primary 
antibody rabbit anti-TMIGD1 diluted 1:400 in blocking agent. Cells were washed 3 times 
in PBS and incubated for 45 minutes in secondary antibody CY3-anti rabbit (Invitrogen), 
diluted 1:500 in blocking agent. Cells were washed 3 times in PBS and incubated for 15 
minutes in Alexa Fluor 488® phalloidin (Thermo Fisher Scientific), diluted 1:500 in 
blocking agent. Cells were washed 3 times in PBS and the coverslips were mounted onto 
slides using VECTASHIELD Mounting Media with DAPI (Vector Laboratories). Images 
were taken using an Olympus BH2-RFCA microscope and attached Olympus DP73 
camera. 
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RNA Extraction  
Cell lines: 500,000 HTR8/SVneo cells were seeded on 6-well plates and incubated at 
37°C for 24 hours. Cells were washed with cold PBS and lysed with 350 μl of Buffer 
RLT (RNeasy Mini Kit, Qiagen, cat # 74104). After vortexing, lysate was mixed with 
equal volume of cold 70% ethanol and transferred to RNeasy spin column placed in 2 mL 
collection tube. The sample was centrifuged for 15 sec at 10,000 rpm, then washed with 
Buffer RW1 (Qiagen) and spun again. DNase I (Qiagen, cat #79254) was added directly 
onto column membrane to destroy DNA. Sample was washed again with Buffer RW1 
and Buffer RPE. Flow-through was discarded after every wash. Purified RNA was eluted 
from membrane using 30 μL RNase-free water. RNA quantification was performed on a 
BioTek microplate reader using Gen5™ software.  
 
Placenta tissue: Tissue was collected into cytowash, divided into 30 mg pieces, and 
transferred to 1 ml of cold Trizol in a 2 ml centrifuge tube. Contents were homogenized 
for 90 seconds, then incubated on ice for 5 minutes. 200 ul chloroform was added to 
tubes and vortexed for 15 seconds. After incubating at room temperature for 5 minutes, 
tubes were centrifuged at 12,000 g for 10 minutes at 4°C. The upper aqueous phase was 
transferred to a new tube and cell pellet was discarded. The RNA-containing liquid was 
treated according to the aforementioned protocol, starting with the equal volume addition 
of 70% ethanol.  
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Reverse Transcription 
The SuperScript® III First-Strand Synthesis System (Life Technologies, cat#18080051) 
was used to synthesize complementary DNA to isolated RNA. This kit provided the 
following reagents and optimized protocol for the reactions. All incubation steps were 
completed in an Applied Biosystems® GeneAmp® PCR System 9700. 0.5-2 ug of RNA 
sample was mixed with 1 ul each of random hexamers (50 ng/ul) and dNTP mix (10mM) 
in a PCR tube, and the solution volume was brought up to 10 ul using RNase-free water. 
After incubation at 65°C for 5 minutes, the denatured product was placed on ice for at 
least 1 minute before being gently mixed with 10 ul of cDNA synthesis mix (Table 1).  
 
Table 1. cDNA Synthesis Mix 
Reagent Volume for each sample (ul) 
10X RT buffer 2  
25mM MgCl2  4 
0.1M DTT 2  
40 U/ul RNaseOUT 1  
SuperScript III reverse transcriptase 1  
Total volume 10 
 
The annealing step was performed at 25°C for 10 minutes before incubation at 50°C for 
50 minutes to allow for cDNA synthesis. The reaction was terminated by increasing the 
temperature to 85°C for 5 minutes, and then placing the PCR tubes on ice. Lastly, 1 ul of 
RNase H was added to each sample, and the tubes were incubated at 37°C for 20 minutes 
to remove leftover RNA. An extra tube with RNase-free water replacing the SuperScript 
III reverse transcriptase was created as a negative control in each experiment. The 
synthesized cDNA was stored at -20°C until qPCR. 
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Quantitative Polymerase Chain Reaction (qPCR) 
Reactions were completed with either iTaq™ Universal SYBR® Green Supermix (Bio-
rad, cat#:172-5121) or TaqMan® Gene Expression Assays according to Table 2 and Table 
3, respectively. For both types of reactions, the housekeeping gene GAPDH was used as 
an internal control. RNase-free water was used in place of cDNA as a negative control. 
 
 
Table 2. qPCR mixture with SYBR® primers 
Reagent Volume for each reaction (ul) 
SYBR® Green Supermix (2X) 8 
Primer mix 2 
cDNA 2 
RNase-free water 4 
Total volume 16 
 
 
Table 3. qPCR mixture with Taqman® primers 
Reagent Volume for each reaction (ul) 
TaqMan® Gene Expression Master Mix 10 
Primer mix 1 
RNase-free water 7 
cDNA 2 
Total volume 20 
 
 
Reagents were mixed in 96-well plates, which were sealed before placing in an Applied 
Biosystems 7500 Real-Time PCR System. qPCR reactions performed with SYBR® or 
TaqMan® followed the thermocycling conditions in Table 4 and Table 5, respectively. 
Data was collected during the 60°C step of each cycle (marked with asterisks). Cycle 
thresholds were normalized using GAPDH results and duplicate samples were averaged. 
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Table 4. Thermocycling with SYBR®  
Stage Temperature (°C) Time 
Initialization 95 5 min 
35 cycles 
95 30 sec 
60* 1 min 
72 30 sec 
Hold 72 10 min 
Hold 95 15 sec 
Hold 60 1 min 
 
 
 
Table 5. Thermocycling with TaqMan® 
Stage Temperature (°C) Time 
Initialization 95 10 min 
40 cycles  
95 15 sec 
60* 1 min 
 
 
Cell Lines 
The immortalized extravillous trophoblast-derived HTR8/SVneo cell line was cultured at 
37°C in RPMI 1640 media (Fisher Scientific) with 10% fetal bovine serum (Life Science) 
and 1% penicillin/streptomycin (Life Technologies, 100X). Cells were grown in 10 mm 
cell culture dishes (BD Falcon), dislodged using 0.25% Trypsin-EDTA, and passed at 90-
100% confluence. 
 
Viral transduction 
HTR8/SVneo cells were grown in 6 cm cell culture plates to 70-80% confluence before a 
16-hour transduction period by a pMSCV retroviral vector with a cloned in Myc-tagged 
TMIGD1 or by an empty vector control. 1ug of Polybrene was added to each plate to 
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increase efficacy of viral uptake. After a 48-hour recovery period, plates were treated 
with puromycin for 96 hours to select for successfully transduced cells. 
 
 
Wound-healing assay 
Untransduced and transduced TMIGD1-overexpressing HTR8/SVneo cells were grown 
to 100% confluence in 12-well plates before scratches were made by 1000 ul pipette tips. 
Quadruplicates of both cell lines were produced, and photographed at 0-hour, 24-hour, 
and 48-hour timepoints. The wound areas were calculated using ImageJ and the degree of 
migration was assessed as the percentage change in wound area after 24 and 48 hours. 
Unpaired t-tests were performed to quantify the relative migration of untransduced 
HTR8/SVneo cells and transduced TMIGD1-overexpressing HTR8/SVneo cells. The 
migration of transduced cells was expressed relative to untransduced cells. 
 
Transwell Migration Assay 
10,000 HTR8/SVneo cells were suspended in serum-free RPMI and seeded onto 
transwell membranes with 8.0 μm size pores. 500 μl of RPMI with 10% FBS was added 
to each well to prompt cell migration. Cells were incubated for 16 hours at 37°C, and 
membranes were washed with PBS. The upper surface of membranes were wiped with 
cotton Q-tips to remove non-invading cells. Membranes were washed with PBS again, 
and cells were treated with Diff-Quik fixation and staining solutions for 90 seconds each. 
Membranes were washed with distilled water and removed from transwells using a razor 
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blade. Stained cells were viewed under a light microscope, and images were taken using 
an Olympus BH2-RFCA microscope and attached Olympus DP73 camera.  
 
Invasion Assay  
10,000 HTR8/SVneo cells were suspended in serum-free RPMI and seeded onto Matrigel 
(diluted 1:8) coated transwell membranes with 8.0 μm size pores. The assay was carried 
out according to the above protocol for the transwell migration assay. 
 
Western Blot Analysis 
Cells were grown in 10 cm cell culture plates to 100% confluence before lysis. Cell plates 
were washed twice on ice with H/S buffer, then lysed with 250 ul of lysis buffer. Lysate 
was collected into centrifuge tube using a cell scraper and centrifuged at 12000 rpm for 
15 minutes at 4°C. Supernatant was isolated and diluted 4: 1 using 5X loading buffer, and 
boiled for 5 minutes at 95°C. 40 ul of cell lysate and 6 ul of ladder were loaded into wells 
of a 4–20% Mini-PROTEAN® TGX™ Gel, and run at 50 mA until protein bands reached 
the gel bottom. Proteins were transferred onto a nitrocellulose membrane in a chamber 
run at 400 mA for 2 hours. The membrane was placed in blocking solution for an hour 
before incubating overnight at 4°C in rabbit anti-TMIGD1 antibody (diluted 1:1000 in 
blocking solution). The membrane was rinsed in washing buffer 3 times for 5 minutes 
each before incubating in horseradish peroxidase (HRP)-anti mouse secondary antibody 
(Santa Cruz) for an hour. Proteins were visualized by treating the membrane with 
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Pierce™ ECL Western Blotting Substrate, and the chemiluminescent signal was exposed 
onto film. As a loading control, the membrane was stripped of antibodies and incubated 
with mouse anti-ERK antibody (diluted 1:1000 in blocking solution) for an hour. 
Membrane treatment was repeated according to the above protocol.  
 
 
Placental Fractionation 
Placenta tissue was collected and rinsed in a solution of sterile PBS and antibiotics 
(amphotericin B, gentamycin, and vancomycin) before being placed on ice in sterile 
DMEM with antibiotics for dissection. Terminal villi were cut off using sterile scissors 
and collected in a vial to be centrifuged for at 1300 rpm for 5 minutes at 4°C. The 
isolated pellet was weighed and proportional amounts of digestive enzyme solutions were 
mixed according to Table 6. After the villi were digested in C1, a drop was checked to 
confirm STB and CTB presence. This was repeated for T1, which was expected to contain 
mostly CTBs and fewer STBs, as well as for T2, which contained CTBs and no 
fibroblasts. The T3 step was carried out to isolate more CTBs while avoiding fibroblasts. 
 
Table 6. Enzyme volumes and incubation times 
Enzyme Amount (mL) Time 
Collagenase1 C1 mass (grams) × 6 6 min 
Trypsin1 T1 mass (grams) × 6 6 min 
Trypsin2 T2 mass (grams) × 5 4.5 min 
Trypsin3 (if needed) T3 20  
Collagenase2 C2 
10 (< 20 grams) 
20 (> 20 grams) 
2.5 min 
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After each step, the supernatant was collected through a sterile gauze filter into a vial and 
diluted with 5 ml of FBS. All supernatants were centrifuged at 1300 rpm for 8 minutes at 
4°C. After discarding the supernatant, the pellets were digested by the C2 step and filtered 
through a cell strainer before another spin. The pellets were resuspended in serum-free 
media, layered on top of a Percoll density gradient, and centrifuged for at 2700 x g for 25 
minutes at 4°C. CTBs and STBs were isolated by extracting specific layers of the 
gradient and washing with sterile DMEM. Cells were counted using a hemocytometer 
and stored in Trizol (ThermoFisher) for future qPCR or in Recovery Cell Culture 
Freezing Medium (Life Technologies). 
 
Statistical analysis 
Data from qPCR, transwell migration assay, wound healing assay, and invasion assay 
were analyzed with ImageJ (NIH) and Microsoft Excel. Significance testing was 
accomplished with un-paired two-tailed t-tests using GraphPad Prism software.  
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RESULTS 
 
TLR4 is a positive marker of villous cytotrophoblasts 
 To accurately assess protein localization in trophoblast layers using 
immunofluorescence, positive markers for the STB and CTB layers are necessary. While 
the use of human placental lactogen (HPL) staining in STBs has been recorded as early as 
1986 (Beck et al., 1986), finding a potential marker for the inner CTB layer has proven 
more challenging. We tested the specificity of Toll-like receptor 4 (TLR4) that Lye et al. 
(2015) successfully localized to the CTB layer of first trimester human placental villi. 
Our antibody against TLR4 showed that its expression is limited to CTB cytoplasm 
(Figure 5A) in a clearly different layer from HPL that we confirmed as localizing in the 
STB layer (Figure 5B). 
 
 
Figure 5. Fluorescent labeling of chorionic villi with TLR4 and HPL antibodies. 
Toll-like receptor 4 (TLR4) specifically localizes to the CTB cytoplasmic region (A), 
while HPL localizes to the STB layer (B). The merged image shows distinct staining of 
layers by the two antibodies (C) in 13-week human placenta. Images taken at 20x 
magnification. Cell nuclei were stained with DAPI. 
 
  
  
 
22 
TMIGD1 localizes to the apical compartment of syncytiotrophoblasts 
To determine where TMIGD1 activity occurs, we aimed to localize TMIGD1 
expression in placental villi using immunofluorescence. 6- and 13-week placental tissue 
was stained using an antibody against TMIGD1, as well as an antibody against human 
placental lactogen (HPL) as an STB layer marker. Figure 6 shows that TMIGD1 is co-
localized with HPL, indicating that TMIGD1 expression is confined to the STB layer. 
Furthermore, TMIGD1 staining was less dispersive, with preferential localization at the 
apical region of STBs as seen in the merged images (panels C and F). 
 
 
Figure 6. Fluorescent labeling of chorionic villi with TMIGD1 and HPL antibodies. 
Human placental lactogen (HPL) was used as a marker for syncytiotrophoblast cells. 
TMIGD1 localizes to the apical region of syncytiotrophoblasts in human placenta at 6 
weeks (A-C) and 13 weeks (D-F) of gestation. Images taken at 20x (D-F) and 40x (A-C) 
magnification. Cell nuclei were stained with DAPI. 
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Increased TMIGD1 expression in transduced HTR8/SVneo cells 
To examine putative function of TMIGD1 in human trophoblasts, we 
overexpressed TMIGD1 in HTR8/SVneo cells, which are an immortalized first trimester 
trophoblast cell line (Graham et al., 1993). 
 
 
Figure 7. TMIGD1 overexpression in HTR8/SVneo cell line. A construct with 
TMIGD1 cloned into a pMSCV retroviral vector was used to transduce HTR8/SVneo 
cells. Staining for TMIGD1 showed expression in the transduced HTR8/SVneo cells (C-
D) compared to empty vector (A-B) and untransduced cells (not shown). Images were 
taken at 20x magnification. Whole cell lysates were blotted for TMIGD1 and loading 
control, ERK 1/2 (E). TMIGD1 mRNA levels were 3-fold higher in the transduced cell 
line and 400-fold higher in first trimester whole placenta, relative to the untransduced cell 
line (F). 
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This was accomplished using a pMSCV retroviral vector containing Myc-tagged 
TMIGD1. HTR8/SVneo cells were also transduced with an empty vector as a negative 
control. TMIGD1 overexpression in HTR8/SVneo cells was verified using 
immunofluorescence; the transduced cell line exhibited more TMIGD1 staining than the 
empty vector cells (Figure 7A-D). Furthermore, protein and mRNA expression levels 
were checked using Western blot and qPCR, respectively (Figure 7E-F). The degree of 
overexpression was quantified using qPCR, which showed that transduced cells displayed 
~3-fold increased TMIGD1 expression compared to that of control cells. In addition, 
human placental tissue expressed more than 400 times more TMIGD1 than the original 
HTR8/SVneo cell line.  
 
 
Increased TMIGD1 expression in HTR8/SVneo cells reduces trophoblast migration 
 Using the modified TMIGD1-overexpressing cell line, we examined whether 
increased TMIGD1 expression affects trophoblast migration. Transduced and control 
HTR8/SVneo cells were seeded onto transwell membranes and allowed to migrate for 16 
hours before fixation and staining. To control for random migration, both cell lines were 
incubated in serum-free media (SFM), while experimental wells contained media with 
fetal bovine serum (FBS). Figure 8 shows that trophoblasts with increased TMIGD1 
expression migrate significantly slower than those with normal TMIGD1 levels. After 
taking into account random movement, we approximated that the increased TMIGD1  
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Figure 8. TMIGD1 overexpression inhibits cell migration in transwell migration 
assay. Migrating HTR8/SVneo cells were fixed and stained with Diff-Quik. 
Representative images were taken of control cells (A) and TMIGD1-overexpressing cells 
(B). Cells incubated in serum-free media (SFM) were used as negative controls for 
random migration. Scale bar indicates 500 μm. An unpaired t-test showed that increased 
TMIGD1 expression reduced migration to 40±10% of controls after 16 hrs (C).  
n=3; *p=0.048 
 
 
expression reduced migration to 40±10% of control cell migration. This supports the idea 
that TMIGD1 may play an inhibitory role in trophoblast invasion.  
We further tested the effect of increased TMIGD1 expression on migration using 
a wound healing assay. Analysis of area changes showed that after 24 and 48 hours, the  
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Figure 9. TMIGD1 overexpression inhibits cell migration in wound healing assay. 
Scratches were made on confluent cells using 1000 ul pipette tips. Photographs were 
taken at 0h, 24h, and 48h time points (not shown), and the wound area was measured 
using ImageJ (A). Unpaired t-tests were performed to quantify the relative migration of 
untransduced HTR8/SVneo cells and transduced TMIGD1-overexpressing HTR8/SVneo 
cells. The migration of transduced cells was expressed relative to untransduced cells. The 
degree of migration was compared separately at 24h (B) and 48h (C). TMIGD1 
overexpression reduced migration to 70±5.25% (p = 0.0001) and 68±4% (p = 0.0008), 
respectively (n=8). 
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TMIGD1-overexpressing cell line displayed significantly slower migration than the 
control cell line (Figure 9). This is consistent with the results of our transwell migration 
assay, as well as a previous study showing that overexpression of TMIGD1 inhibits 
migration of kidney epithelial cells (Arafa et al., 2012). 
 
 
Figure 10. TMIGD1 overexpression inhibits trophoblast invasion in invasion assays. 
Invading HTR8/SVneo cells were fixed and stained with Diff-Quik. Cells incubated in 
serum-free media (SFM) were used as negative controls for random migration. An 
unpaired t-test showed that increased TMIGD1 expression reduced migration to 33±11% 
of controls after 16 hrs. n=3; *p=0.037 
 
 
We performed an invasion assay consisting of Matrigel-coated transwells. 
Matrigel is a gelatinous substance consisting of extracellular matrix components such as 
laminin, collagen IV, and various other proteins. Our results showed that the increased 
TMIGD1 expression reduces trophoblast invasion to 33±11% of the control cell invasion 
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(Figure 10). This supports the idea that TMIGD1 may play an inhibitory role in 
trophoblast invasion during placenta formation. 
 
TMIGD1 overexpression alters cell morphology and actin formation 
Actin formation is essential for many cellular functions, including motility. Thus, 
we chose to examine whether TMIGD1 affects the actin cytoskeleton as a possible 
mechanism by which it affects cell motility. Double labeling of transduced HTR8/SVneo 
cells using an antibody against TMIGD1 and fluorescently-labelled phalloidin showed 
organized actin distribution to the peripheries in cells with increased TMIGD1 expression 
(Figure 11A). In contrast, control cells display actin as filamentous bundles distributed 
randomly throughout (Figure 11B). Additionally, single cells of the control population 
frequently exhibit filopodia, actin-rich protrusions that are important for cell migration 
and wound healing. This was markedly different from the transduced cell population, 
which contained numerous oval-shaped cells with distinct lack of filopodia and actin 
localization to the peripheries (Figure 11C). Our visualization of the actin cytoskeleton is 
consistent with the diminished migration of TMIGD1-overexpressing cells observed in 
prior experiments. 
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Figure 11. TMIGD1 overexpression alters cell morphology and actin formation. 
TMIGD1-overexpressing and control HTR8/SVneo cells were stained for actin using 
fluorescently-labelled phalloidin. Double staining showed actin cytoskeleton of 
TMIGD1-overexpressing cells (A). Distribution of actin in control cells is filamentous 
and disorganized (B, top), while actin in TMIGD1-overexpressing cells localizes to the 
peripheries (B, bottom). Typical structure of lone cells showing that TMIGD1 
overexpression modifies morphology (C). In a population with increased TMIGD1 
expression, fewer cells exhibited this migratory phenotype, compared to that observed in 
a control population. 
 
 
 
Greater TMIGD1 expression in fractionated STBs 
 Comparing expression levels of TMGID1 in CTBs and STBs is useful for 
confirming its localization in chorionic villi by IHC and understanding how TMIGD1 
activity takes part in regulatory mechanisms. Placental tissue was treated with digestive 
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enzymes and centrifuged in a Percoll density gradient to separate the two types of 
trophoblast cells. This was successfully accomplished with placenta of 13- and 15-week 
gestational ages. RNA was isolated from CTBs and STBs, for future cDNA synthesis and 
qPCR analysis. Table 7 shows quantification and purity of these extracts. 
 
Table 7. Purity and concentration of RNA from fractionated CTBs and STBs 
Gestational 
Age 
CTBs STBs 
Concentration 
(ng/uL) 
Purity 
(260/280) 
Concentration 
(ng/uL) 
Purity 
(260/280) 
13 wk 1106.8 1.884 429.2 1.886 
15 wk 97.2 1.869 157.2 1.889 
*260/280 represents the ratio of absorbance when RNA is exposed to ultraviolet light at 
260 and 280 nm. A sample with ratio of ~2 is generally considered pure RNA. 
 
 
 cDNA was synthesized from RNA extracted from 13-week-old CTBs and STBs, 
and TMIGD1 expression of the two cell types was compared using qPCR (Figure 12). 
HPL is known to have greater expression in the STB layer and served as an experimental 
control. Additionally, the housekeeping gene GAPDH was used as an internal control. 
Our results showed that TMIGD1 mRNA levels are 1.62 times higher in STBs than in 
CTBs. This is consistent with our previous fluorescent staining showing localization of 
TMIGD1 to the apical membranes of STBs. Further analysis of fractionated CTBs and 
STBs from additional placentas of various gestational ages are necessary to determine 
statistical significance. 
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Figure 12. TMIGD1 mRNA expression in fractionated STBs and CTBs by qPCR. 
TMIGD1 mRNA levels were 1.62-fold higher in STBs than in CTBs fractionated from 
placenta of 13-week gestational age. HPL was used as an experimental control that is 
known to be preferentially expressed in STBs. mRNA levels were normalized using 
GAPDH. 
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DISCUSSION 
 
TMIGD1 localization in STBs 
 This research describes characteristics of the novel cell adhesion molecule 
TMIGD1 in human trophoblast cells. Trophoblast differentiation and invasion into the 
maternal decidua are highly regulated processes that are crucial for normal placenta 
development. Dysregulation of placental invasion may cause serious complications for 
both mother and fetus. The mechanisms for coordinating trophoblast activity are 
mediated by local factors, including autocrine signals from trophoblasts and paracrine 
signals from the uterus. Based on previous research, we aimed to investigate whether 
TMIGD1 plays a regulatory role in placenta invasion by characterizing its expression and 
activity in human trophoblasts. 
Our study demonstrates that TMIGD1 is expressed at the apical membrane of 
STBs in 1st and 2nd trimester placenta. TMIGD1 localization on the apical membrane of 
STBs suggests that TMIGD1 may interact with factors in the intervillous space or the 
maternal uterine lining. Alternatively, the lack of TMIGD1 in CTBs indicates that its 
expression may be characteristic of trophoblasts in the differentiated STB state that are 
no longer invasive. 
We plan to explore this idea by inducing syncytialization in BeWo 
choriocarcinoma cells using forksolin (Wice et al., 1990) and examining changes in 
TMIGD1 expression post-fusion. Syncytium formation is of utmost importance because 
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it creates an immunological barrier against components of the maternal defense system 
and pathogens (Beer & Sio, 1982; Chucri et al., 2010). The STB layer also secretes the 
hormone human chorionic gonadotropin (hCG), which mediates various processes during 
pregnancy (Cole, 2010). 
qPCR or Western blots may be performed on fractionated STBs and CTBs to 
confirm our staining observations and to quantify the TMIGD1 expression differences 
between the two layers. Isolated STBs may also be stained to detect whether the apical 
localization on STBs is maintained. However, given that the fractionation process 
involves numerous enzymatic digestions, it is possible that membrane proteins may be 
degraded or reorganized. 
We also showed that TLR4 is a reliable CTB marker that may be used for future 
experiments to distinguish the two cell types. This will be particularly useful in future 
immunofluorescence experiments, as well as for checking the purity of isolated CTBs 
and STBs from placental villi after a fractionation process (described in Methods).  
 
TMIGD1 inhibits migration 
 Our immunofluorescence, qPCR, and Western blot data confirmed successful 
transduction of the HTR8/SVneo cell line, thus providing a way to examine TMIGD1 
overexpression. Our wound healing and transwell migration assays showed that increased 
TMIGD1 expression inhibits trophoblast migration, which is consistent with previous 
findings from Arafa et al. in 2015 that TMIGD1 inhibits kidney epithelial cell migration. 
  
 
34 
Our invasion assay further supported the idea that TMIGD1 may play a role in regulating 
trophoblast invasion that must be tightly controlled to achieve normal placental 
attachment and function. HTR8/SVneo invasion through the Matrigel substrate provided 
a more precise assessment of primary trophoblast invasive activity. 
 
TMIGD1 regulates actin assembly 
 Differences in the actin cytoskeleton of control and TMIGD1-overexpressing 
HTR8/SVneo cells indicate that TMIGD1 may directly or indirectly regulate actin 
assembly. One hypothesis is that TMIGD1 is involved in mechanisms controlling cell 
migration, and downstream effectors may determine whether actin distributes to the 
peripheries or assembles as stress fibers and filopodia. A comparable study found that 
epidermal growth factor promotes trophoblast migration, using Rho proteins to mediate 
actin cytoskeleton remodeling (Han et al., 2013). Alternatively (and less likely), 
TMIGD1 may directly affect actin expression and promote redistribution to the 
peripheries, leading to a stable cytoskeletal structure that makes migration difficult. 
 A recent study showed that extravillous trophoblasts develop invadopodia, which 
are actin-rich protrusions that assist in invasion (Patel & Dash, 2012). These specialized 
cellular structures have been characterized in cancer metastasis, and give invading cells 
the ability to degrade extracellular matrix (Buccionie et al., 2009). Our previous 
observations that TMIGD1 may be involved in actin remodeling is relevant for studying 
invadopodia function and the invasive properties of trophoblasts. 
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A greater proportion of non-motile cells in the transduced HTR8/SVneo 
population, as revealed by a survey of cell morphology, is consistent with our findings 
that increased TMIGD1 inhibits migration. This phenotype also suggests mechanical 
stability, and we may examine the potential mechanism between actin assembly, 
TMIGD1, and adhesive properties of trophoblasts in the future. 
 
Proposed model of TMIGD1 expression 
 Given the specific localization of TMIGD1 to STB apical membrane and the 
inhibitory effect of increased TMIGD1 on trophoblast migration and invasion, we 
theorize that TMIGD1 is involved in regulating placenta invasion according to Figure 13. 
TMIGD1 may serve as a “stop” signal for cytotrophoblast invasiveness. Villous CTBs 
(yellow) are progenitors of multinucleated STBs (blue) in the outer layer of placenta villi, 
as well as of extravillous cytotrophoblasts (green) that invade the maternal decidua. 
Further studies are necessary to elucidate the significance of TMIGD1 localization to the 
apical region of STBs, as well as to identify potential molecules that may interact with 
TMIGD1. Additionally, it is worth analyzing TMIGD1 expression in placenta of different 
gestational ages. Given the potential role of TMIGD1 in regulating placenta invasion, it 
may also be involved in the etiology of pregnancy disorders involving abnormal invasion. 
Further research will examine diseased placenta tissue from preeclamptic and growth-
restricted pregnancies to detect altered patterns of TMIGD1 expression. 
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Figure 13. Proposed model of TMIGD1 expression during placental invasion. Inner 
layer CTBs have the potential to differentiate into STBs (blue) or extravillous 
cytotrophoblasts (green), which proceed to invade the maternal decidua. The role of 
TMIGD1 (purple), located at the apical region of STBs, is yet unknown. 
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